What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Modified version of parathyroid hormone attached to vitamin D to extend half-life”In the company’s words, NCT06988670 on ClinicalTrials.gov
- Tested for
- Hypoparathyroidism
- Main trialPhase 2
- “The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.”In the company’s words, NCT06988670 on ClinicalTrials.gov
- Other names
- test drug
Other drugs for Hypoparathyroidism
- PalopegteriparatideAscendis Pharma A/S · Phase 3
- CanvuparatideMBX Biosciences · Phase 3
- EncaleretCalcilytix Therapeutics, Inc., a BridgeBio company · Phase 3
- EneboparatideAlexion Pharmaceuticals, Inc. · Phase 3
- AMOR-1Amorphical Ltd. · Phase 2
Coming up1
- May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | May 2027 | A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism | |
| Phase 1Completed | 13 Jun 2023 | A Phase 1 Study of EXT608 in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026